Product Description
Dong-A was developing da-5202, and injectable drug, for the treatment of osteoarthritis of the knee (Sourced from https://clinicaltrials.gov/ct2/show/NCT02554240)
Mechanisms of Action: Unknown
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dong-A
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
DA5202_KOA_II | P2 |
Completed |
Osteoarthritis, Knee |
2016-06-29 |
24% |